Publications by authors named "R Palop"
Prospective application of a bleeding and ischemic risks-adjusted antithrombotic protocol in elderly patients revascularized with everolimus-eluting stents: EPIC05-Sierra75 study.
J Geriatr Cardiol
May 2022
Article Synopsis
- The study aimed to evaluate the outcomes of elderly patients (over 75 years) undergoing percutaneous transluminal coronary intervention (PCI) using an antithrombotic strategy that considers their individual risks for bleeding and ischemic events.
- The research included 1,064 patients and found that the incidence of major adverse cardiovascular events and bleeding was lower in this tailored treatment group compared to a control group, with no cases of stent thrombosis in those receiving shorter dual antiplatelet therapy.
- The conclusion indicates that a risk-adjusted antithrombotic protocol for elderly patients after revascularization with the latest stent technology may lead to better health outcomes regarding both bleeding and ischemic events.
Everolimus drug-eluting stent performance in patients with long coronary lesions: The multicenter Longprime registry.
Catheter Cardiovasc Interv
December 2018
Objectives: To assess the efficacy and safety of the Xience Prime everolimus-eluting stent (EES) in long coronary lesions in a real-world population.
Background: Long lesions are considered difficult technically and in terms of achieving successful clinical outcomes. With first generation DES, MACE can be as high as 10% at a short-medium term follow-up.
Background: No randomized studies have thus far evaluated intravascular ultrasound (IVUS) guidance in the drug-eluting stent (DES) era. The aim was to evaluate if IVUS optimized DES implantation was superior to angiographic guidance alone in complex lesions.
Methods: Randomized, multicentre, international, open label, investigator-driven study evaluating IVUS vs angiographically guided DES implantation in patients with complex lesions (defined as bifurcations, long lesions, chronic total occlusions or small vessels).
Background: A myocyte enhancer factor 2A (MEF2A) mutation that segregated with coronary artery disease/myocardial infarction (CAD/MI) in a large family has recently been described. Missense mutations in sporadic coronary artery disease patients were also reported. These data suggest that mutations in exons 7 and 11 of MEF2A cause CAD/MI, though the association was refuted by another study.
View Article and Find Full Text PDFBackground: This study has analysed the trend of antihypertensive drugs consumption in Spain from 1985 to 1995, its economical impact and the correlation with the available scientific evidence. The utilization of calcium channel blockers in the context of the recent controversial about their safety profile was also evaluated.
Methods: Drugs from the ATC groups C02, C03 (excluding C03C), C07, C08 (excluding nimodipine and nicardipine) and C09 were included (ATC classification, 1996 version).